127 results about "Proliferative capacity" patented technology

The invention discloses a detection method for rapid real-time drug effect evaluation and application of the detection method. The detection method comprises the following steps: providing a quantitative corresponding relation between a same-generation calibration change value of electrical characteristics caused by physiological changes such as cell same-representative characteristics and the like and the cell proliferation ability; adhering to-be-detected cells to the surface of the same membrane electrode; applying the medicine to be detected, and observing the same generation measurement change value of the electrical characteristics in a cell proliferation cycle; and based on the quantitative corresponding relationship, obtaining the drug effect of the corresponding real-time proliferation characteristic evaluation drug. According to the detection method provided by the invention, the physiological changes such as the same-representative characteristics of the adherent cells are monitored through the membrane electrode, and after the quantitative corresponding relation between the change indexes of the same-representative characteristics of the cells and the proliferation capacity of the cells is established, the cell proliferation capacity is detected; the change of the cell proliferation capacity can be predicted through physiological changes such as the same representative characteristics of the cells before proliferation and apoptosis of the cells, so that the judgment period of the influence of the medicine on the cells can be greatly shortened, and the progress of medicine evaluation and research and development can be remarkably accelerated.

The invention discloses a culture method of high-activity human urine-derived stem cells, which relates to the technical field of biological medicine, and is technically characterized by comprising the following steps: collecting urine samples of pregnant and lying-in women, coating a culture plate with gelatin, inducing adherence, performing passage amplification, performing immunofluorescence identification, performing function detection and other optimized conditions, and separating and culturing the stem cells. Compared with urine-derived stem cells of normal adults, the stem cells derived from pregnant women have stronger activity, higher dryness and faster multiplication capacity. The invention provides a novel and superior cell source for tissue engineering and regenerative medicine.

The invention relates to a serum-free culture medium for culturing mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. Wherein the serum-free culture medium comprises a complete culture medium and praeruptorin E, and the content of the praeruptorin E in the serum-free culture medium is 0.25-3 [mu] M. The inventor finds that a serum-free culture medium containing a certain concentration of praeruptorin E can effectively improve the decline of replicative activity of mesenchymal stem cells in in-vitro passage. Specifically, the serum-free culture medium containing the praeruptorin E with a certain concentration can reduce the expression level of a marker beta-galactosidase with reduced replicative activity in the mesenchymal stem cells with reduced replicative activity after multiple in-vitro passage, reduce the expression of a gene CDKN1A with reduced replicative activity, and increase the multiplication capacity of the mesenchymal stem cells; the mitochondrial damage is reduced.

The invention discloses a method for wrapping stem cells by adopting programmable DNA (deoxyribonucleic acid) hydrogel and application of the method, under isothermal physiological conditions, three-dimensional DNA hydrogel is formed through a hybridization chain reaction of an initiation chain (I) and hairpin structure DNA to realize reversible wrapping and release of the stem cells. The hairpin structure DNA is formed by denaturation-renaturation treatment of at least two DNA monomer building blocks, and the mechanical rigidity of the hydrogel is realized by regulating and controlling the molar ratio of the initiation chain (I) to the total amount of the DNA monomer building blocks; the DNA hydrogel can reversibly wrap and release stem cells, and the wrapped stem cells can maintain activity and dryness and recover normal multiplication capacity after being released. According to the method disclosed by the invention, the activity and dryness of the stem cells are remarkably maintained, obvious immune activation is avoided, and the method provides a brand new tool for in-vitro culture and engineering application of the stem cells and has a wide application prospect.

The invention provides an immortalized NK cell line SZ093 derived from healthy human umbilical cord blood as well as a preparation method and application of the immortalized NK cell line SZ093. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood is preserved in Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, and has high killing capacity on tumor cells.

The invention discloses nucleus pulposus cells as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the steps that exosomes are collected from immortalized spherical nucleus pulposus cells and used for culturing the nucleus pulposus cells, the cultured nucleus pulposus cells have higher multiplication capacity, and large-scale in-vitro amplification of the nucleus pulposus cells is achieved; meanwhile, the cultured nucleus pulposus cells have higher extracellular matrix secretion capacity. The cultured nucleus pulposus cells are used for treating the intervertebral disc degeneration disease, the clinical use requirement can be met, and an effective treatment scheme is provided for treating the intervertebral disc degeneration disease.

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

To provide: a cell culture vessel that can achieve both detachability and proliferation ability, that is, can facilitate cell detachment without reducing the proliferation ability of cells; and a cell detachment method using the cell culture vessel, provided is a cell detachment method of detaching, through use of a culture vessel having a periodic recess / protrusion pattern on a culture surface, comprising a detachment step of: causing a vibrating unit in which, when an observation image of a cross section perpendicular to the culture surface is obtained, a length Lcp of a contour of the cell on the culture surface side in a measurement region of the observation image and a length Lf of the measurement region in a direction parallel to the culture surface satisfy Lcp>Lf; and transmitting the ultrasonic vibration to the cell, to thereby detach the cell from the culture surface.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dirithromycin in preparation of a product for treating LINC00516 high-expression lung adenocarcinoma. The invention discloses the effect of the long-chain non-coding RNA LINC00516 in abnormal activation of the lung adenocarcinoma cell cycle for the first time. Researches show that LINC00516 is directly combined with CDK1, the kinase activity of CDK1 is remarkably enhanced, and the inhibitory phosphorylation level of CDK1 is reduced, so that lung adenocarcinoma cells are driven to quickly enter a G2 / M phase, and tumor cell proliferation is accelerated. The invention further innovatively proposes that dirithromycin is used as an intervention means, and by blocking the combination of LINC00516 and CDK1, the activity of CDK1 is effectively reduced, and the proliferation capacity of tumor cells is inhibited. In-vivo and in-vitro experiments prove that the dirithromycin can obviously inhibit the growth of lung adenocarcinoma cells with high expression of LINC00516, so that a brand-new molecular targeting treatment strategy is provided for clinic.

The process provided in this invention transfects primary cells with gene editing reagents using a high-volume gas-permeable cell culture device and a flow-through electroporation device under conditions that improve gene editing performance, cell yield, and drug (DP) quality characteristics for cell therapy applications. As demonstrated in the examples, primary cells edited according to the process provided herein achieved improved double-strand break (DSB) formation rates, increased frequency of homology-directed repair (HR) and non-homologous end joining (NHEJ) combinations, increased frequency of bi-allelic and mono-allelic HR events, improved cell viability, proliferative capacity, and cell fitness after gene editing, and reduced manufacturing time.

The invention relates to a mesenchymal stem cell serum-free culture medium with limited chemical components as well as application and a method thereof, the serum-free culture medium is completely serum-free and has definite components: all additives are known chemical substances and meet the production requirements of cGMP (Complementary Good Manufacturing Practice); telomere shortening can be obviously delayed; replicative senescence is slowed down by activating TERT expression; the multiplication capacity can also be enhanced; the P10 generation cells still have the active division capacity; multidirectional differentiation is supported; the osteogenic differentiation efficiency is superior to that of a traditional serum-containing system; and the method is suitable for industrial production and clinical transformation.

This invention provides a chimeric antigen receptor comprising an NFIX-encoding gene, a self-cleaving peptide sequence F2A, and a CAR-encoding sequence. The NFIX-encoding gene is located upstream and is linked to the CAR-encoding sequence via the self-cleaving peptide sequence F2A. The sequence of the NFIX-encoding gene is shown in SEQ ID NO. 01, and the sequence of the self-cleaving peptide sequence F2A is shown in SEQ ID NO. 03. This invention also provides a chimeric antigen receptor T cell expressing the aforementioned chimeric antigen receptor. This invention further provides the application of the aforementioned chimeric antigen receptor or the aforementioned chimeric antigen receptor T cell in the preparation of drugs for treating cancer. This invention improves the antitumor therapeutic effect of CAR-T cells by introducing the NFIX expression element into engineered T cells, thereby enhancing their functional stability, proliferative capacity, and cytotoxic activity under continuous antigen stimulation.

The present invention relates to a method for selecting a donor source for NK cells with enhanced proliferative capacity, wherein specific single nucleotide polymorphisms (SNPs) of the CISH gene are identified. According to the present invention, in the context of cell therapy including NK cells, the method solves the problem that the efficacy of NK cells differs according to the difference of donor sources, thereby enabling the production of NK cells having excellent proliferation ability and stable quality.

The invention provides application of Mybl2 protein in preparation of a medicine for repairing heart injury, and belongs to the technical field of biological medicine. The invention provides an application of Mybl2 protein in preparation of a medicine for repairing heart injury. The medicine comprises overexpressed Mybl2 protein. Mybl2 overexpression can significantly increase the proportion of myocardial cell proliferation and promote expression of cell cycle related proteins, Mybl2 participates in maintaining the proliferation capacity of myocardial cells, and overexpression can effectively promote myocardial cell proliferation and is a potential new target for myocardial regeneration.

The invention discloses an application of SB216763 in improving the in-vitro proliferation capacity of porcine spermatogonium. Therefore, the SB216763 can be used as an additive of the porcine spermatogonial cell in-vitro culture medium, and the porcine spermatogonial cell in-vitro culture medium combined with various growth factors is prepared. Researches show that clone groups of the porcine spermatogonium cultured by the culture medium additionally added with the SB216763 are increased, the number of the clone groups is remarkably increased, the expression quantity of genes related to proliferation is remarkably increased, apoptosis genes are remarkably reduced, and the expression of genes related to reproductive specificity and pluripotent maintenance is also increased, so that the in-vitro proliferation and long-term maintenance of the porcine spermatogonium are improved, and the porcine spermatogonium can be used for preparing a novel culture medium for the porcine spermatogonium. Therefore, the in-vitro culture level of the PSCs is systematically improved. Therefore, the invention provides a reliable basis for establishing a long-term, stable and efficient in-vitro culture system of the porcine spermatogonium, and provides a stable and efficient cell model for gene editing of the porcine spermatogonium, preparation of transgenic animals and research on reproductive diseases; the method also has potential application value in the aspects of genetic improvement of pig breeds or preservation of male germplasm resources.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.

The application discloses immortalized chicken embryo epithelioid cells and a preparation method and application thereof, and the preparation method of the immortalized chicken embryo epithelioid cells comprises the following steps: extracting primary chicken embryo epithelial cells from a chicken embryo; and culturing the primary chicken embryo epithelioid cells in a conditional medium containing chicken Noggin protein for subculture, so as to obtain the immortalized chicken embryo epithelioid cells. The immortalized chicken embryo epithelioid cells prepared by the preparation method can be stably subcultured for a long time, can maintain stable proliferation ability after multiple subcultures, reduces individual differences, and improves the reliability and repeatability of experimental results. In addition, the preparation method does not introduce exogenous genes or change the genotype of the cells, ensures the stability at the gene level, and avoids the interference of the exogenous genes on the stability of the cell phenotype.

Disclosed are use of a circRNA molecule as a diagnostic marker in a cell senescence diagnosis kit, and use thereof as a treatment target for cell senescence. The present invention finds that circHERC1 is lowly expressed in both cell models of natural senescence and induced senescence. Overexpression of circHERC1 in endothelial cells can improve the proliferation capacity of the endothelial cells, effectively extend the telomere length of the cells, activate telomerase, reduce the β-galactosidase positive rate of the cells, and reduce the expression of all senescence-associated proteins. Introduction of exogenous circHERC1 into mice can effectively delay the senescence of various organs and the shortening of telomeres in aged mice and reduce the β-galactosidase positive rates of various organs of aged mice.

The invention provides a human diploid stably transfected cell line suitable for coxsackie virus A6 culture and application of the human diploid stably transfected cell line. The construction of the human diploid stably transfected cell line comprises the steps of construction of an hKREMEN1 lentivirus overexpression vector, virus packaging and stably transfected cell screening. The problem that proliferation of the CVA6 virus in human diploid cells is not ideal is solved, the human KREMEN1 gene is over-expressed in the human diploid cells (KBM17) by utilizing a lentivirus technology, and the proliferation capacity of the CVA6 virus on the KMB17 cells is improved by constructing the KMB17 cells capable of stably expressing hKREMEN1 receptors, so that a good foundation is laid for research and development of hand-foot-and-mouth disease vaccines; vaccine preparation and effectiveness evaluation are facilitated.

Provided is an improved method for preparing tumor-infiltrating lymphocytes, the method comprising removing Treg cells that inhibit the activity of effector T cells or converting Treg cells into CD8+ effector T cells, whereby the tumor-infiltrating lymphocytes have excellent ability to kill tumor cells and excellent proliferative ability.

The invention discloses a p16-OSKM transgenic mouse model and a reprogramming senescence cell construction method and application, and belongs to the technical field of cell biology and regenerative medicine. According to the method, a p16-OSKM hybrid mouse capable of specifically inducing an OSKM factor in a p16 high expression cell is obtained on the basis of hybridization of a p16-Ink4a-CreERT2 transgenic mouse, a Rosa26-CAG-LSL-rtTA3-IRES-mKate2 transgenic mouse and a Col1a1-TRE-OSKM-IRES-mCherry transgenic mouse. The selective activation of the OSKM factor in senescent cells with high expression of p16 can be realized by adding doxycycline into primary embryo fibroblasts separated from the mouse under an in-vitro culture condition, so that the senescent cells enter a cell cycle again and recover division and multiplication capacities. The technology provides an accurate model platform for basic research, and can be used for aging mechanism exploration, cell fate regulation and control, chronic disease treatment, development and screening of anti-aging drugs and the like.

The application discloses a method for separating and culturing primary vascular smooth muscle cells from human abdominal aortic wall, and relates to the technical field of human cell culture. The method comprises the following steps: obtaining a collagenase A solution; adding the collagenase A solution to a treated human abdominal aortic aneurysm wall tissue sample and then cutting the sample; transferring the cut human abdominal aortic aneurysm wall tissue sample to a 37-degree cell culture box for culture; centrifuging a cell suspension obtained after termination of digestion; discarding supernatant, resuspending cell precipitate, and repeating centrifugation for three times; resuspending the cell precipitate again, uniformly transferring the cell precipitate to a T25 culture bottle after blowing, and placing the cell precipitate in a 37-degree cell culture box for culture; when a wave peak and wave trough state appears, the cell precipitate is digested and subcultured by using 0.25% trypsin, and then the cell precipitate is transferred to a new T25 culture bottle; and the cell precipitate is subcultured normally to the P3 generation and then stored in liquid nitrogen, so that the cell damage is prevented and the activity and proliferation capacity of the cell are maintained.

The invention relates to a CD70 and BCMA targeting dual-targeting chimeric antigen receptor and an application thereof. The CD70 and BCMA targeting dual-targeting chimeric antigen receptor has specific binding ability to CD70 and BCMA. The immune effector cell prepared on the basis of the double-targeting chimeric antigen receptor has the following advantages that the probability that tumor cells escape treatment by losing a single antigen is greatly reduced, and the targeting treatment effect is improved; a CD70 nano antibody sequence is used, so that the length of an insertion fragment is greatly shortened, and the development difficulty of a process end is reduced; and the polypeptide has excellent proliferation capacity, is beneficial to prolonging the in-vivo duration time, and plays a more remarkable anti-tumor role. The invention provides a treatment or improvement approach for diseases related to BCMA-CD70 expression.

The invention provides a method for enriching Tcm cells and application thereof, and particularly, the method comprises the step of performing first co-culture on a T cell population and stem cell exosomes. The exosome secreted by the stem cells contains a plurality of active proteins, RNA, lipids, metabolites and other molecules for keeping the dryness of the cells, the stem cell exosome and the T cell population are co-cultured, and the stem cell exosome can keep the rejuvenation of the T cells in the culture process and induce the differentiation of the T cells to the Tcm cells, so that the proportion of the Tcm cells is increased, and the cell proliferation rate is increased. High cell viability and proliferation capacity are maintained, and guarantee is provided for the function exertion of the T cells and related cell products thereof.

The invention provides an AIE photosensitizer with a cell membrane targeting function as well as a preparation method and application of the AIE photosensitizer. The AIE photosensitizer has the following structure shown in the specification. Under the action of illumination, the TTP-Mems can induce generation of a large amount of ROS in the toxoplasma gondii bodies, typical ultrastructure damage such as cell membrane rupture and collapse is caused, and rapid inactivation of the free toxoplasma gondii is achieved. Meanwhile, the photosensitizer treatment can significantly inhibit the formation of plaques of polypide bodies in host cells, reduce the invasion, replication and multiplication capacities, and show clear in-vitro toxoplasma gondii resistance activity.

The present invention relates to an FLT3-CAR-γδT cell co-expressing a cytokine and a use thereof. Specifically, the present invention provides an engineered CAR-γδT cell targeting FLT3, wherein the CAR-γδT cell co-expresses an IL-2 or IL-7 cytokine, maintains a high stemness level and proliferation capacity, and has a sustained tumor cell killing ability. The FLT3-CAR-γδT cell co-expressing a cytokine of the present invention demonstrates persistent killing ability and anti-tumor activity against acute myeloid leukemia (AML) tumor cells in multiple in vitro and in vivo experiments, has high safety and wide applicability, and has application prospects in the field of AML therapy.

The invention belongs to the technical field of cell culture, and particularly relates to a bone marrow mesenchymal stem cell culture medium and a preparation method and application thereof. The mesenchymal stem cell culture medium comprises a basic culture medium, and betaine, glycyrrhizin, insulin, EGF (Epidermal Growth Factor), L-propyl dipeptide and naloxicol which are added into the basic culture medium. The bone marrow mesenchymal stem cell culture medium can effectively improve the multiplication capacity of bone marrow mesenchymal stem cells, delay cell senescence and improve the osteogenic differentiation capacity of the bone marrow mesenchymal stem cells, fetal calf serum is not added, the risk of introducing heterologous serum to carry viruses is avoided, and the safety of clinical application is improved.